Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director · President | May 27, 2025 | May 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date May 27, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,806,642 |
Reported balance
After 2025-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-27 · Sale · Disposed 2,000 · Balance 2,806,642 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,806,084 |
Reported balance
After 2025-05-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-28 · Sale · Disposed 558 · Balance 2,806,084 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 29, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 558 | $10.07 | $5,619.06 |
DisclosureSEC source: 0001140361-25-020754 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,806,084 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 27, 2025 Filed May 29, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.28 | $20,560.00 |
DisclosureSEC source: 0001140361-25-020754 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,806,642 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2025 Filed May 27, 2025 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 182 | $10.24 | $1,863.68 |
DisclosureSEC source: 0001140361-25-020474 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,808,642 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.97 | $21,940.00 |
DisclosureSEC source: 0001140361-25-020474 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,808,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.215 to $11.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.83 | $21,660.00 |
DisclosureSEC source: 0001140361-25-020156 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,810,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.32 to $11.275. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.25 | $22,500.00 |
DisclosureSEC source: 0001140361-25-020156 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,812,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.925 to $11.42. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.11 | $22,220.00 |
DisclosureSEC source: 0001140361-25-019893 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,814,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.02 to $11.215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.31 | $22,620.00 |
DisclosureSEC source: 0001140361-25-019893 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,816,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.82 to $11.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.68 | $21,360.00 |
DisclosureSEC source: 0001140361-25-019468 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,818,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.435 to $10.93. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 20 | $11.30 | $226.00 |
DisclosureSEC source: 0001140361-25-019468 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,820,824 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at price of $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 13, 2025 Filed May 14, 2025 20:04 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.37 | $22,740.00 |
DisclosureSEC source: 0001140361-25-018927 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,820,844 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.16 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2025 Filed May 14, 2025 20:04 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.56 | $21,120.00 |
DisclosureSEC source: 0001140361-25-018927 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,822,844 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.885. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 174 | $10.00 | $1,740.00 |
DisclosureSEC source: 0001140361-25-010234 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,824,844 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.005. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.09 | $20,180.00 |
DisclosureSEC source: 0001140361-25-009877 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,825,018 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.13 | $20,260.00 |
DisclosureSEC source: 0001140361-25-009877 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,827,018 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 242 | $10.24 | $2,478.08 |
DisclosureSEC source: 0001140361-25-009424 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,829,018 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.09 | $24,180.00 |
DisclosureSEC source: 0001140361-25-009424 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,829,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.795 to $12.38. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.31 | $24,620.00 |
DisclosureSEC source: 0001140361-25-009017 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,831,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.06 to $12.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.80 | $23,600.00 |
DisclosureSEC source: 0001140361-25-009017 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,833,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.51 to $11.97. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.74 | $23,480.00 |
DisclosureSEC source: 0001140361-25-008623 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,835,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.135. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.40 | $22,800.00 |
DisclosureSEC source: 0001140361-25-008623 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,837,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.92 to $11.845. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.14 | $20,280.00 |
DisclosureSEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 4 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,839,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,906 | $10.13 | $19,307.78 |
DisclosureSEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,841,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.365. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 41 | $12.14 | $497.74 |
DisclosureSEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,843,166 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 53 | $13.03 | $690.59 |
DisclosureSEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,843,207 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.80 to $13.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.80 | $21,600.00 |
DisclosureSEC source: 0001140361-25-007602 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,843,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.63 to $11.17. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.98 | $21,960.00 |
DisclosureSEC source: 0001140361-25-007602 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,845,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.63 to $11.23. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.86 | $21,720.00 |
DisclosureSEC source: 0001140361-25-007173 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,847,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.03. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.23 | $22,460.00 |
DisclosureSEC source: 0001140361-25-007173 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,849,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.95 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.41 | $22,820.00 |
DisclosureSEC source: 0001140361-25-006738 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,851,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.33 | $22,660.00 |
DisclosureSEC source: 0001140361-25-006738 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,853,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.18 to $11.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.63 | $23,260.00 |
DisclosureSEC source: 0001140361-25-006273 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,855,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $11.86. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 21:02 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.37 | $22,740.00 |
DisclosureSEC source: 0001140361-25-006273 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,857,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.20 to $11.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 187 | $11.52 | $2,154.24 |
DisclosureSEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 4 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,859,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.43 to $11.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,813 | $10.60 | $19,217.80 |
DisclosureSEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,859,447 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.41 to $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 182 | $12.60 | $2,293.20 |
DisclosureSEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,861,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.71. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,818 | $11.84 | $21,525.12 |
DisclosureSEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,861,442 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.54 to $12.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.40 | $24,800.00 |
DisclosureSEC source: 0001140361-25-005420 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,863,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.15 to $12.61. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.29 | $24,580.00 |
DisclosureSEC source: 0001140361-25-005420 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,865,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.1 to $12.62. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.49 | $24,980.00 |
DisclosureSEC source: 0001140361-25-005113 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,867,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.26 to $12.78. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.94 | $23,880.00 |
DisclosureSEC source: 0001140361-25-005113 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,869,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.78 to $12.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 21:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.69 | $23,380.00 |
DisclosureSEC source: 0001140361-25-004744 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,871,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.59 to $11.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.49 | $22,980.00 |
DisclosureSEC source: 0001140361-25-004744 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,873,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.645. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 01:45 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,878 | $11.52 | $21,634.56 |
DisclosureSEC source: 0001140361-25-004126 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,875,260 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.45 to $11.61. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2025 Filed Feb 13, 2025 01:45 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.90 | $23,800.00 |
DisclosureSEC source: 0001140361-25-004126 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,877,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.72 to $12.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.16 | $24,320.00 |
DisclosureSEC source: 0001140361-25-003831 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,879,158 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.01 to $12.475. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2025 Filed Feb 11, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.85 | $25,700.00 |
DisclosureSEC source: 0001140361-25-003831 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,881,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.70 to $13.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 20 | $12.84 | $256.80 |
DisclosureSEC source: 0001140361-25-003426 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,883,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.835 to $12.84. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,980 | $12.39 | $24,532.20 |
DisclosureSEC source: 0001140361-25-003426 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,883,158 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.82 to $12.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.62 | $23,240.00 |
DisclosureSEC source: 0001140361-25-003426 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,885,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.33 to $11.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.